Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2012

Kirou KA, Gkrouzman E, Chevalier JM, Seshan SV. Antiinflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al. Arthritis Rheum. 2012;64(10):3486; author reply 3486.

Olson MT, Wakely PE, Weber K, Siddiqui MT, Ali SZ. Postradiation sarcoma: morphological findings on fine-needle aspiration with clinical correlation. Cancer Cytopathol. 2012;120(5):351-7.

Gable AD, Clark SH, Magro CM. Myxoid variant of anaplastic large cell lymphoma involving the skin: a case report. J Cutan Pathol. 2012;39(8):787-90.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012;18(11):1699-704.

Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, et al. Wnt signaling though beta-catenin is required for prostate lineage specification. Dev Biol. 2012;371(2):246-55.

An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.

Osmundson J, Montero-Diez C, Westblade LF, Hochschild A, Darst SA. Promoter-specific transcription inhibition in Staphylococcus aureus by a phage protein. Cell. 2012;151(5):1005-16.

Panciani PP, Fontanella M, Tamagno I, Battaglia L, Garbossa D, Inghirami G, et al. Stem cells based therapy in high grade glioma: why the intraventricular route should be preferred? J Neurosurg Sci. 2012;56(3):221-9.

Johnson H, Cohen C, Fatima N, Duncan D, Siddiqui MT. Thyroid transcription factor 1 and Napsin A double stain: utilizing different vendor antibodies for diagnosing lung adenocarcinoma. Acta Cytol. 2012;56(6):596-602.

Sengupta A, Chakraborty S, Paik J, Yutzey KE, Evans-Anderson HJ. FoxO1 is required in endothelial but not myocardial cell lineages during cardiovascular development. Dev Dyn. 2012;241(4):803-13.